文献速递生殖医学

外源性促性腺激素剂量对PGT-A周期胚胎非整倍体率及妊娠结局的影响

[Effect of exogenous gonadotropin dosage on embryo aneuploidy rate and pregnancy outcome in patients of preimplantation genetic test].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2020-01-01

回顾性分析402个PGT-A周期(338例患者)的临床资料,按Gn累积用量分为≤2 250 U与>2 250 U两组。结果显示Gn用量与胚胎非整倍体率及妊娠结局均无显著关联,女方年龄增长增加非整倍体风险(OR=1.031,95%CI 1.010~1.054,P=0.004),获卵数增加降低非整倍体风险(OR=0.981,95%CI 0.971~0.991,P<0.01)。

要点

  • PGT-A周期中Gn累积用量与胚胎非整倍体率无关。
  • Gn用量对生化妊娠率、临床妊娠率及活产率均无显著影响。
  • 高龄患者获卵数增加可能降低胚胎非整倍体风险。

核心结论

  • PGT-A周期中Gn累积使用量与胚胎非整倍体率及妊娠结局无关。
  • 女方年龄是影响PGT-A周期胚胎非整倍体率的重要因素。
  • 在≥35岁患者中获卵数增加可能降低胚胎非整倍体率。

研究设计与样本

  • 回顾性分析2013年1月1日至2019年5月31日解放军总医院第一医学中心行PGT-A患者的临床资料。
  • 共纳入402个周期(338例患者)、1 883个胚胎。
  • 按年龄分低龄(<35岁)与高龄(≥35岁),按Gn累积用量分≤2 250 U与>2 250 U。
  • 按获卵数分1~5个、6~10个、11~15个、≥16个四组。
  • 采用logistic回归分析Gn累积用量与胚胎非整倍体及活产率的关系。

主要发现

  • 低龄患者中Gn≤2 250 U组胚胎非整倍体率52.5%(304/579),Gn>2 250 U组48.6%(188/387),差异无统计学意义(P=0.232)。
  • 高龄患者中Gn≤2 250 U组胚胎非整倍体率57.9%(208/359),Gn>2 250 U组60.6%(319/526),差异无统计学意义(P=0.420)。
  • 高龄患者中各获卵数组胚胎非整倍体率分别为73.6%(89/121)、57.5%(119/207)、56.3%(108/192)、57.8%(211/365),差异有统计学意义(P=0.046)。
  • logistic回归显示女方年龄增长增加胚胎非整倍体风险(OR=1.031,95%CI 1.010~1.054,P=0.004),获卵数增加降低非整倍体风险(OR=0.981,95%CI 0.971~0.991,P<0.01)。
  • 不同Gn用量组间生化妊娠率[55.6%(80/144) vs 52.1%(63/121)]、临床妊娠率[50.0%(72/144) vs 47.9%(58/121)]、活产率[46.5%(67/144) vs 40.5%(49/121)]均无差异(P=0.613、0.738、0.324)。

关键数值与推荐

  • PGT-A周期中Gn累积用量与胚胎非整倍体率不相关(P=0.885)。
  • 女方年龄增长增加胚胎非整倍体风险(OR=1.031,95%CI 1.010~1.054,P=0.004)。
  • 获卵数增加减少胚胎非整倍体风险(OR=0.981,95%CI 0.971~0.991,P<0.01)。
  • 女方年龄、Gn累积使用量、获卵数、卵巢刺激方案对活产率均无影响(P均>0.05)。

临床怎么用

  • PGT-A周期中Gn用量选择可不以降低胚胎非整倍体率为考量依据。
  • 高龄患者可通过增加获卵数来降低胚胎非整倍体风险。
  • 女方年龄是PGT-A周期胚胎非整倍体的重要预测因素。

局限性

  • 回顾性研究设计。
  • 单中心数据。
  • 黄体期方案样本量少(低龄6/13,高龄5/9)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the effect of gonadotropin (Gn) on embryo aneuploidy rate and pregnancy outcome during preimplanptation genetic testing for aneuploidy (PGT-A) cycles. Methods: The clinical data of patients undergoing PGT-A cycle at the First Medical Center of the PLA General Hospital from January 1, 2013 to May 31, 2019 were retrospectively analyzed. Patients were divided into younger patient group (<35 years old) and elder patient group (≥35 years old) by maternal age, then divided into two groups in line with Gn dosage (≤2 250 U, >2 250 U), and into four groups by number of oocytes retrieved (1-5, 6-10, 11-15 and ≥16 oocytes). The embryo aneuploidy rate and pregnancy outcome between the groups were compared. Logistic regression was used to analyze the relationship between the cumulative amount of Gn, embryo aneuploidy rate and live-birth rate. Results: A total of 402 cycles (338 patients) and 1 883 embryos were included in the study. (1) In the younger patients, the aneuploidy rate was 52.5% (304/579) in the group of Gn≤2 250 U and 48.6% (188/387) in the group of Gn>2 250 U, with no significant difference between them (P=0.232). In the elderly patients, the difference in embryo aneuploidy rate between the two Gn group [57.9% (208/359) versus 60.6% (319/526)] was not statistically significant (P=0.420). (2) The embryonic aneuploidy rate in different protocol of ovary stimulation was analyzed,in the younger group, the embryonic aneuploidy rate in patients using antagonist long protocol was 50.3% (158/314), it was 50.0% (121/242) in agonist long protocol, 52.1% (207/397) in agonist short protocol and 6/13 in luteal phase protocol, no statistical difference was found in above groups (P=0.923); in the elder group, embryonic aneuploidy rate was 60.8% (191/314) in antagonist protocol, 58.4% (132/226) in agonist long protocol, 59.2%(199/336) in agonist short protocol, 5/9 in luteal phase protocol, respectively,no significant difference was found (P=0.938). (3) In the younger patients, the aneuploidy rate in 1-5 oocytes group, 6-10 oocytes group, 11-15 oocytes group and ≥16 oocytes group was 37.9% (11/29), 54.0% (94/174), 52.5% (104/198) and 50.1% (283/565) respectively, no significant difference was found between the groups (P=0.652); while in the elder patients, the difference between aneuploidy rate in each retrieved oocytes group [73.6% (89/121), 57.5% (119/207), 56.3% (108/192), 57.8% (211/365)] was statistically significant (P=0.046). (4) Logistic regression analysis of age, cumulative dosage of Gn, number of oocytes obtained, and embryo aneuploidy rate showed that there was no association between the amount of Gn and embryo aneuploidy rate (P>0.05); the increase in maternal age would increase the risk of aneuploidy rate of embryos, which was statistically significant (OR=1.031, 95%CI: 1.010-1.054, P=0.004); the increase in oocytes retrived would significantly decrease the risk of aneuploidy (OR=0.981, 95%CI: 0.971-0.991, P<0.01). (5) There was no significant difference in biochemical pregnancy rate [55.6% (80/144) versus 52.1% (63/121)], clinical pregnancy rate [50.0% (72/144) versus 47.9% (58/121)] and live-birth rate [46.5% (67/144) versus 40.5% (49/121)] between different Gn dosage groups (P=0.613, P=0.738, P=0.324). The logistic regression analysis showed that the maternal age, the cumulative dosage of Gn, the number of oocytes obtained, and the ovarian stimulation protocol had no effect on the live-birth rate (all P>0.05). Conclusions: In PGT-A cycle, the dosage of Gn has no association with the embryo aneuploidy rate and pregnancy outcome. In the patients ≥35 years old, the increase in number of oocytes obtained may decrease the risk of aneuploidy. Age is an important factor affecting the embryo aneuploidy in PGT-A cycle. 目的: 探讨胚胎植入前遗传学非整倍体检测(PGT-A)周期中,促性腺激素(Gn)对胚胎非整倍体率及妊娠结局的影响。 方法: 回顾性分析2013年1月1日至2019年5月31日在解放军总医院第一医学中心行基于二代测序技术的PGT-A患者的临床资料,按年龄分为低龄(<35岁)与高龄(≥35岁),根据Gn累积使用量分为≤2 250 U、>2 250 U,根据获卵数分为1~5个、6~10个、11~15个、≥16个,比较不同患者间的胚胎非整倍体率及PGT-A临床结局的差异,采用logistic回归探讨Gn累积使用量与胚胎非整倍体及活产率间的关系。 结果: 共有402个周期(338例患者)、1 883个胚胎纳入本研究。(1)在低龄患者中,Gn≤2 250 U者的胚胎非整倍体率为52.5%(304/579),与Gn>2 250 U者的48.6%(188/387)比较,差异无统计学意义(χ(2)=1.430,P=0.232);在高龄患者中,两者的差异[分别为57.9%(208/359)、60.6%(319/526)]同样无统计学意义(χ(2)=0.649,P=0.420)。(2)在低龄患者中,使用促性腺激素释放激素(GnRH)拮抗剂方案的患者胚胎非整倍体率为50.3%(158/314),GnRH激动剂长方案者为50.0%(121/242),GnRH激动剂短方案者为52.1%(207/397),黄体期方案者为6/13,各方案间无差异(χ(2)=0.482,P=0.923);在高龄患者中,各卵巢刺激方案间的差异[分别为60.8%(191/314)、58.4%(132/226)、59.2%(199/336)、5/9]也无统计学意义(χ(2)=0.410,P=0.938)。(3)在低龄患者中,获卵数1~5个者的胚胎非整体率为37.9%(11/29),6~10个者为54.0%(94/174),11~15个者为52.5%(104/198),≥16个者为50.1%(283/565),均无差异(P=0.652);但在高龄患者中,胚胎的非整倍体率分别为73.6%(89/121)、57.5%(119/207)、56.3%(108/192)、57.8%(211/365),差异有统计学意义(P=0.046)。(4)logistic回归分析显示,Gn累积使用量与胚胎非整倍体不相关(P=0.885),女方年龄的增长会增加发生胚胎非整倍体的风险(OR=1.031,95%CI为1.010~1.054,P=0.004),获卵数的增加会减少发生非整倍体的风险(OR=0.981,95%CI为0.971~0.991,P<0.01)。(5)不同Gn用量患者间的生化妊娠率[分别为55.6%(80/144)、52.1%(63/121)]、临床妊娠率[分别为50.0%(72/144)、47.9%(58/121)]、活产率[分别为46.5%(67/144)、40.5%(49/121)]均无差异(P=0.613、0.738、0.324);logistic回归分析显示,女方年龄、Gn累积使用量、获卵数、卵巢刺激方案对活产率均无影响(P均>0.05)。 结论: PGT-A周期中,Gn累积使用量与胚胎非整倍体率及妊娠率无关,在≥35岁的高龄患者中,获卵数增加可能降低胚胎非整倍体率,年龄是影响PGT-A周期中胚胎非整倍体率的重要因素。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang JN, Wang J, Peng HM, et al. [Effect of exogenous gonadotropin dosage on embryo aneuploidy rate and pregnancy outcome in patients of preimplantation genetic test]. Zhonghua Fu Chan Ke Za Zhi. 2020. PMID: 32375432. doi:10.3760/cma.j.cn112141-20200309-00198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。